NeoGenomics, Inc. NEO
Set alert
17.38 USD -0.55 -3.07%
At close
17.24 -0.14 -0.81%
Pre-market · Nov 2, 8:08 AM ET
17.09 Day range 18.14
7.07 52-week range 20.15
- YTD
- +47.79%
- 1 year
- +77.89%
- Open
- 17.95
- Prev close
- 17.93
- Mkt cap
- 2.25B
- Vol
- 1.46M
- Avg vol
- 2.03M
- EPS
- -0.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.09
- High
- 18.14
- Forward P/E
- 52.76
- Beta
- 0.00
- Short ratio
- 5.78
- Inst. own
- 115.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 16, 2027
- 50-d avg
- 17.67
- 200-d avg
- 12.76
- 1y target
- 23.33
2Y chart
Events in this range
- Oct 28, 2025Earnings: 0.03; estimate 0.02; surprise 50%
- Feb 17, 2026Earnings: 0.06; estimate 0.04; surprise 50%
- Apr 28, 2026Earnings: 0.01; estimate 0.00578; surprise 73.01%
- Jul 28, 2026Earnings: 0.05; estimate 0.03355; surprise 49.03%
- Jul 29, 2026Rating: Needham · Buy → Buy
- Oct 6, 2026Rating: BTIG · Neutral → Buy
- Oct 6, 2026Rating: Needham · Buy → Buy
- Oct 6, 2026Rating: StoneX · Buy → Buy
- Oct 28, 2026Earnings: 0.07; estimate 0.05546; surprise 26.22%
- Oct 29, 2026Rating: BTIG · Buy → Buy
- Oct 29, 2026Rating: TD Cowen · Buy → Buy
Signals (91)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 5 days ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| RSI: Overbought | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| RSI: Overbought | Jun 11, 2026 | 4 months ago |
| RSI: Overbought | Jun 9, 2026 | 4 months ago |
| RSI: Overbought | Jun 4, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 28, 2026 | 6 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 4, 2026 | 8 months ago |
| RSI: Oversold | Mar 4, 2026 | 8 months ago |
| RSI: Oversold | Mar 2, 2026 | 8 months ago |
| RSI: Oversold | Feb 18, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 20, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 9, 2025 | 10 months ago |
| RSI: Overbought | Dec 3, 2025 | 11 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 28, 2025 | 1 year ago |
| RSI: Overbought | Oct 23, 2025 | 1 year ago |
| RSI: Overbought | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 17, 2025 | 1 year ago |
| RSI: Overbought | Aug 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| RSI: Oversold | Jul 29, 2025 | 1 year ago |
| RSI: Oversold | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 29, 2025 | 1 year ago |
| RSI: Oversold | Apr 29, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 9, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 8, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 25, 2025 | 1 year ago |
| RSI: Oversold | Feb 21, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
| RSI: Overbought | Dec 6, 2024 | 1 year ago |
| RSI: Overbought | Nov 22, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.23B
- Enterprise value
- 2.63B
- Trailing P/E
- 0.00
- Forward P/E
- 52.76
- PEG ratio
- 2.09
- Price / sales
- 2.83
- Price / book
- 2.78
- EPS (TTM)
- -0.24
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -4.10%
- Revenue (TTM)
- 787.75M
- Revenue growth
- 11.40%
- Free cash flow
- -17.24M
- Total cash
- 139.28M
- Total debt
- 449.14M
- Return on equity
- -3.94%
- Shares outstanding
- 129.39M
- Short % of float
- 12.98%
- 50-day average
- 17.67
- 200-day average
- 12.76
Analyst view
Consensus: buy
Buy
Price target (mean) 23.33 +34.3% upside
Now 17.38
- Target (low)
- 19.00
- Target (mean)
- 23.33
- Target (high)
- 35.00
Ratings (0m) 11 8 buy · 3 hold · 0 sell
- Strong buy2
- Buy6
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 0.06667.
Financials — quick view
NEO Revenue — quarterly 209.25M
NEO Net income — quarterly -7.55M
NEO EPS — quarterly -0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 0.06 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.05546 | 0.07 | +0.01 | +26.22% |
| Jul 28, 2026 | Jun 30, 2026 | 0.03355 | 0.05 | +0.02 | +49.03% |
| Apr 28, 2026 | Mar 31, 2026 | 0.00578 | 0.01 | 0.00 | +73.01% |
| Feb 17, 2026 | Dec 31, 2025 | 0.04 | 0.06 | +0.02 | +50.00% |
| Oct 28, 2025 | Sep 30, 2025 | 0.02 | 0.03 | +0.01 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | TD Cowen | main | Buy | Buy |
| Oct 29, 2026 | BTIG | reit | Buy | Buy |
| Oct 6, 2026 | StoneX | main | Buy | Buy |
| Oct 6, 2026 | Needham | main | Buy | Buy |
| Oct 6, 2026 | BTIG | up | Neutral | Buy |
| Jul 29, 2026 | Needham | main | Buy | Buy |
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- neogenomics.com
News
- NEO Battery Reports Fiscal Year 2027 Second Quarter Results
- TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23
- What NeoGenomics (NEO) Said on Its Q3 Earnings Call
- NeoGenomics Q3 2026 Earnings Call Transcript
- NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est
- NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate
- NeoGenomics Reports Third Quarter 2026 Results
- What's Going On With NeoGenomics Stock Tuesday?
- General Motors To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
- StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20
Your note
Sign in to keep a note on NEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANNAH ALISON L. | Director | Conversion of Exercise of derivative security | May 29, 2025 | 131,023 |
| HARRIS MELODY | Officer | Conversion of Exercise of derivative security | Feb 20, 2025 | 109,755 |
| KANOVSKY STEPHEN MICHAEL | Director | Conversion of Exercise of derivative security | May 31, 2026 | 75,421 |
| KELLY MICHAEL AARON | Director | Conversion of Exercise of derivative security | May 31, 2026 | 72,086 |
| OLIVO ALICIA C | General Counsel | Conversion of Exercise of derivative security | May 10, 2026 | 93,567 |
| SHERMAN JEFFREY SCOTT | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 22, 2026 | 220,009 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.13% | 20,868,362 | 359.35M | Jun 29, 2026 |
| First Light Asset Management, LLC | 9.49% | 12,279,523 | 211.45M | Jun 29, 2026 |
| First Trust Advisors LP | 7.82% | 10,113,261 | 174.15M | Jun 29, 2026 |
| Greenhouse Funds, LLLP | 6.63% | 8,574,210 | 147.65M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.23% | 8,061,362 | 138.82M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.45% | 5,763,017 | 99.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.91% | 7,648,512 | 131.71M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 4.96% | 6,416,474 | 110.49M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.20% | 4,136,535 | 71.23M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 3,359,516 | 57.85M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.31% | 2,985,348 | 51.41M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.04% | 2,645,940 | 45.56M | May 30, 2026 |